Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 31-40 of 2796 for

Edit search filters
  1. Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ

  2. A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

    Scottsdale/Phoenix, AZ

  3. Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  4. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  5. Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

    Jacksonville, FL, Rochester, MN

  6. OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  7. A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

    Rochester, MN

  8. Combination Vaccine Immunotherapy (DRibbles) for Patients with Definitively-treated Stage III Non-small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  9. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

    Rochester, MN

  10. Cyclophosphamide and Vaccine Therapy in Treating Patients with Stage II-III Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Rochester, MN

.

Mayo Clinic Footer